Lukas Rob

Lukas Rob

Auto-generated profile, based on publicly available information

Lukas Rob

Department of Obstetrics and Gynaecology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague 10, Czech Republic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JFJitka Fucikova
Jitka Fucikova
MHMichal Hensler
Michal Hensler
LKLenka Kasikova
Lenka Kasikova
TLTereza Lanickova
Tereza Lanickova
JPJosef Pasulka
Josef Pasulka
RSRadek Spisek
Radek Spisek
Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management of various solid tumors has raised considerable expectations for patients with epithelial ovarian carcinoma (EOC). However, EOC is poorly responsive to ICIs due to immunologic features including limited tumor mutational burden (TMB) and poor lymphocytic infiltration. An autologous dendritic cell (DC)-based vaccine (DCVAC) has recently been shown to be safe and to significantly improve progression-free survival (PFS) in a randomized phase II clinical trial enrolling patients with EOC (SOV01, NCT02107937). Patients and Methods: We harnessed sequencing, flow cytometry, multispectral immunofluorescence microscopy, and IHC to analyze (pretreatment) tumor and (pretreatment and posttreatment) peripheral blood samples from 82 patients enrolled in SOV01, with the aim of identifying immunologic biomarkers that would improve the clinical management of patients with EOC treated with DCVAC. Results: Although higher-than-median TMB and abundant CD8+ T-cell infiltration were associated with superior clinical benefits in patients with EOC receiving standard-of-care chemotherapy, the same did not hold true in women receiving DCVAC. Conversely, superior clinical responses to DCVAC were observed in patients with lower-than-median TMB and scarce CD8+ T-cell infiltration. Such responses were accompanied by signs of improved effector functions and tumor-specific cytotoxicity in the peripheral blood. Conclusions: Our findings suggest that while patients with highly infiltrated, “hot” EOCs benefit from chemotherapy, women with “cold” EOCs may instead require DC-based vaccination to jumpstart clinically relevant anticancer immune responses.

20 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
TLTereza Lanickova
Tereza Lanickova
MHMichal Hensler
Michal Hensler
LKLenka Kasikova
Lenka Kasikova
SVSarka Vosahlikova
Sarka Vosahlikova
AAArtemis Angelidou
Artemis Angelidou
JFJitka Fucikova
Jitka Fucikova
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics and targeted anticancer agents that not only mediate cytotoxic effects but also promote the recruitment of immune effector cells to the HGSOC microenvironment stand out as promising combinatorial partners for ICIs in this oncological indication. Experimental Design: We harnessed a variety of transcriptomic, spatial, and functional assays to characterize the differential impact of neoadjuvant paclitaxel-carboplatin on the immunological configuration of paired primary and metastatic HGSOC biopsies as compared to neoadjuvant chemotherapy (NACT)-naïve HGSOC samples from five independent patient cohorts. Results: We found NACT-driven endoplasmic reticulum stress and calreticulin exposure in metastatic HGSOC lesions culminates with the establishment of a dense immune infiltrate including follicular T cells (TFH cells), a prerequisite for mature tertiary lymphoid structure (TLS) formation. In this context, TLS maturation was associated with an increased intratumoral density of ICI-sensitive TCF1+PD1+ CD8+ T cells over their ICI-insensitive TIM-3+PD1+ counterparts. Consistent with this notion, chemotherapy coupled with a PD1-targeting ICI provided a significant survival benefit over either therapeutic approach in syngeneic models of HGSOC bearing high (but not low) tumor mutational burden. Conclusions: Altogether, our findings suggest that NACT promotes TLS formation and maturation in HGSOC lesions, de facto preserving an intratumoral ICI-sensitive T-cell phenotype. These observations emphasize the role of rational design, especially relative to the administration schedule, for clinical trials testing chemotherapy plus ICIs in patients with HGSOC. See related commentary by Bravo Melgar and Laoui, p. 10

19 January 2024 in Surgical and Radiologic Anatomy
Verified
Journal Article
Closed access
PDF file
JZJan Zapletal
Jan Zapletal
ONOndrej Nanka
Ondrej Nanka
MHM. J. Halaska
M. J. Halaska
KMKateřina Maxová
Kateřina Maxová
LHL. Hajkova Hympanova
L. Hajkova Hympanova
LRL. Rob
L. Rob

5 August 2006 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
RTRuth Tachezy
Ruth Tachezy
IMI. Mikyšková
I. Mikyšková
VLV. Ludvíková
V. Ludvíková
LRL. Rob
L. Rob
TKTomáš Kučera
Tomáš Kučera
EHE. Hamšíková
E. Hamšíková

16 January 2025 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
BSBorek Sehnal
Borek Sehnal
MHMartin Hruda
Martin Hruda
RMRadoslav Matej
Radoslav Matej
HRHelena Robova
Helena Robova
JDJana Drozenova
Jana Drozenova
PDPavel Dundr
Pavel Dundr
The International Federation of Gynaecology and Obstetrics (FIGO) introduced a new staging system for endometrial carcinoma FIGO 2023 in June 2023. The new staging system differs significantly from previous versions by incorporating other non-anatomical parameters (histological type of tumour, tumour grade and the presence of massive lymphovascular space involvement as well as the molecular classification of the tumour). The FIGO 2023 staging system enhances the accuracy of prognostic assessments for patients at a specific stage with better options for targeted treatment. Another objective was to synchronise staging as much as possible with the European oncogynaecological ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma established in 2021. However, several changes are controversial. Routine molecular classification of endometrial carcinomas is not yet commonly available in most countries of the world. Another limitation of the FIGO 2023 staging system of endometrial cancer is the inclusion of variables whose definitions are still evolving, as well as variables that are subject to considerable interobserver variability in their assessment. Advantages, controversies, and limitations for clinical practice of the new FIGO 2023 endometrial cancer staging system are discussed.

13 October 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
VHViktor Hlavac
Viktor Hlavac
PHPetr Holý
Petr Holý
RVRadka Václavíková
Radka Václavíková
LRLukáš Rob
Lukáš Rob
MHMartin Hruda
Martin Hruda
Pavel SoucekPavel Soucek
Pavel Soucek
Epithelial ovarian carcinoma (EOC) is highly fatal because of the risk of resistance to therapy and recurrence. We performed whole-exome sequencing of blood and tumor tissue pairs of 50 patients with surgically resected EOC. Compared with sensitive patients, platinum-resistant patients had a significantly higher somatic mutational rate inTP53and lower in several genes from the Hippo pathway. We confirmed the pivotal role of somatic mutations in homologous recombination repair genes in platinum sensitivity and favorable prognosis of EOC patients. Implementing the germline homologous recombination repair profile significantly improved the prediction. In addition, distinct mutational signatures, for example, SBS6, and overall mutational load, somatic mutations inPABPC1,PABPC3, andTFAMco-segregated with the resistance status, high-grade serous carcinoma subtype, or overall survival of patients. We generated germline and somatic genetic landscapes of prognostically different subgroups of EOC patients for further follow-up studies focused on utilizing the observed associations in precision oncology.